Caxton Associates LP raised its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 466,110 shares of the company’s stock after buying an additional 34,924 shares during the quarter. Caxton Associates LP’s holdings in Allogene Therapeutics were worth $1,086,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in shares of Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after purchasing an additional 1,806,147 shares during the period. Affinity Asset Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at $1,284,000. Susquehanna Fundamental Investments LLC bought a new stake in Allogene Therapeutics during the 1st quarter worth about $1,280,000. TD Asset Management Inc increased its position in Allogene Therapeutics by 82.7% in the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock valued at $1,862,000 after acquiring an additional 361,904 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Allogene Therapeutics by 4.1% in the second quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock worth $13,212,000 after acquiring an additional 221,840 shares during the last quarter. 83.63% of the stock is owned by institutional investors.
Allogene Therapeutics Trading Up 3.8 %
NASDAQ:ALLO opened at $2.72 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $2.01 and a 1 year high of $5.78. The stock has a 50-day moving average price of $2.67 and a two-hundred day moving average price of $2.97. The stock has a market cap of $568.78 million, a price-to-earnings ratio of -1.52 and a beta of 0.83.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on ALLO shares. Canaccord Genuity Group dropped their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Piper Sandler started coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They issued an “overweight” rating and a $11.00 price objective on the stock. Citigroup upped their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Oppenheimer assumed coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.96.
Get Our Latest Report on Allogene Therapeutics
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Recommended Stories
- Five stocks we like better than Allogene Therapeutics
- ESG Stocks, What Investors Should Know
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Best Stocks Under $10.00
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report).
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.